B
BCRX
Biocryst Pharmaceuticals Inc
8.55
+0.26+3.14%After Hours: 8.55 0.00 0.00%19:30 10/09 EDT
OPEN/PREV CLOSE8.27/8.29
TODAY RANGE8.27-8.60
VOL2.31M
MARKET CAP2.18B
52 WEEK RANGE6.00-11.22
AVG VOL (3M)4.11M
% TURNOVER0.66%
TURNOVER--
P/E (TTM)-5.6848
% RANGE3.92%
EPS(TTM)-1.5040
P/E(FORWARD)-3.7019
P/B-4.8042
BVPS-1.7797
DIVIDEND--
P/S2.082
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.02B
SHARES OUTSTANDING255.54M
NEXT EARNINGS11/02-11/06
FREE FLOAT236.10M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·2d ago
RBC Capital Sticks to Its Hold Rating for BioCryst (BCRX)
Simply Wall St·3d ago
BioCryst Pharmaceuticals (BCRX) Names Scientific Advisory Board, Is The Discount Too Wide?
Simply Wall St·6d ago
Did New Science Board Just Shift BioCryst's (BCRX) Investment Narrative?
Dow Jones·09/30 18:04
BioCryst Pharmaceuticals Is Maintained at Neutral by JP Morgan
Benzinga·09/30 17:55
JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13
TipRanks·09/30 11:30
BioCryst price target raised to $13 from $12 at JPMorgan
Seeking Alpha·09/24 13:39
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Simply Wall St·09/24 05:27
Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative
Seeking Alpha·09/23 15:26
BofA identifies Russell 2000 stocks positioned for Fed hiking cycles
Simply Wall St·09/20 10:17
BioCryst Pharmaceuticals (BCRX) Puts Orladeyo Growth And Valuation Back In Focus
NASDAQ·09/19 02:01
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
Seeking Alpha·09/15 17:15
Undervalued healthcare stocks with attractive valuation grades
TipRanks·09/15 15:36
3 Best Stocks With 140%+ Upside to Buy This Week, According to Analysts